News

Vertex Reports Second Quarter 2025 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended ...
Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which Apel ...